Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today

October 18, 2010 By Bio-Medicine.Org

THOUSAND OAKS, Calif., Oct. 18 /PRNewswire-FirstCall/ — Amgen
(Nasdaq:
AMGN
) will review the results from TREAT (the Trial to Reduce
Cardiovascular Events with Aranesp® Therapy) and will discuss
how these results inform the appropriate use of
erythropoiesis-stimulating agents (ESAs) for chronic renal failure
(CRF) patients at today’s meeting of the Food and Drug
Administration’s (FDA) Cardiovascular and Renal Drugs Advisory
Committee (CRDAC).

“This advisory committee meeting is a valuable forum for the
FDA, Amgen and the nephrology community to review the results from
TREAT, which further inform use of ESAs in patients with chronic
renal failure who are not on dialysis,” said Reshma Kewalramani,
M.D., FASN, executive director, Global Development at Amgen. “We
look forward to sharing our analyses of TREAT and describing
proposed label changes that will help guide nephrologists in
focusing their use of ESA therapy on patients most likely to
benefit.”

TREAT, the largest study of ESA use in CRF patients to date, is
a randomized, double-blind, placebo-controlled, Phase 3 study of
patients with moderate kidney dysfunction who were not on dialysis,
had moderate anemia and type-2 diabetes and were treated to a
hemoglobin target of 13 g/dL, a higher level than recommended in
the current approved ESA label. The study did not meet its
endpoints of demonstrating a reduction in all-cause mortality,
cardiovascular morbidity or end-stage renal disease and showed an
increased risk of stroke in the Aranesp (darbepoetin alfa) arm,
among other key findings.

The results from TREAT provide important information about the
cardiovascular risks of treating CRF patients with ESAs to a
hemoglobin target of 13 g/dL or greater. Cardiovascular risks have
been reflected in the boxed warning of the FDA-approved ESA labels
since 2007 and, in December 2009, Amgen further strengthened
the

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of ResMed President and COO Rob Douglas
ResMed finds a solution to semiconductor shortage, as well as some humor in it
Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech